MapLight Therapeutics (MPLT) Payables (2024 - 2026)
MapLight Therapeutics (MPLT) posted Payables of $3.3 million for Q4 2025, up 34.46% sequentially from $2.4 million in Q3 2025, and up 72.02% YoY from $1.9 million in Q4 2024.
Powered by 
Analysis
MapLight Therapeutics (MPLT) Payables (2024 - 2026) Analysis & Trends
MapLight Therapeutics has reported Payables for 2 years, with the latest figure at $3.3 million in Q4 2025.
- Quarterly Payables rose 72.02% year-over-year to $3.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.3 million (up 72.02% YoY) and the FY2025 annual result came in at $3.3 million, up 72.02% from the prior year.
- Payables improved to $3.3 million in Q4 2025 per MPLT's latest filing, from $2.4 million in the prior quarter.
- Over five years, Payables peaked at $3.3 million in Q4 2025 and troughed at $1.9 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 167.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 88.42 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 470.30 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 35.57 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 10 | MapLight Therapeutics | 642.40 Mn | 642.40 Mn | - | 2.05 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.05 Mn |
| Dec 31, 2025 | 3.29 Mn |
| Sep 30, 2025 | 2.45 Mn |
| Dec 31, 2024 | 1.91 Mn |